Page last updated: 2024-10-30

metformin and Hepatitis C

metformin has been researched along with Hepatitis C in 11 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.

Research Excerpts

ExcerptRelevanceReference
"A combination of metformin, peginterferon alfa-2a, and ribavirin improved insulin sensitivity and increased the SVR rate of patients with hepatitis C genotype 1 and IR, with a good safety profile."9.16The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. ( Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH, 2012)
"Secondary outcomes include changes in liver fibrosis using AST to platelet ratio index, changes in glucose and lipid levels, anthropometric measures, changes in alpha-fetoprotein levels, patient acceptability, and changes in dietary and physical activity parameters."6.82Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. ( Cooper, C; Doyle, MA; Lee, T; Muir, M; Singer, J, 2016)
"A combination of metformin, peginterferon alfa-2a, and ribavirin improved insulin sensitivity and increased the SVR rate of patients with hepatitis C genotype 1 and IR, with a good safety profile."5.16The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. ( Kang, P; Sun, LJ; Yan, BZ; Yu, JW; Zhao, YH, 2012)
" The main risk factors for developing HCC are well known and include hepatitis B and C virus infection, alcohol intake and ingestion of the fungal metabolite aflatoxin B1."4.93Hepatocellular carcinoma. ( Gores, G; Llovet, JM; Pikarsky, E; Sangro, B; Schwartz, M; Sherman, M; Zucman-Rossi, J, 2016)
"Secondary outcomes include changes in liver fibrosis using AST to platelet ratio index, changes in glucose and lipid levels, anthropometric measures, changes in alpha-fetoprotein levels, patient acceptability, and changes in dietary and physical activity parameters."2.82Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. ( Cooper, C; Doyle, MA; Lee, T; Muir, M; Singer, J, 2016)
"Hepatocellular carcinoma is the most common primary liver malignancy, commonly a sequelae of hepatitis C infection, but can complicate cirrhosis of any cause."1.46Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. ( Kasmari, AJ; Leslie, D; Liu, G; McGarrity, T; Riley, T; Welch, A, 2017)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (81.82)24.3611
2020's2 (18.18)2.80

Authors

AuthorsStudies
Talebi, A1
Kargar, M1
Abdel Monem, MS1
Farid, SF1
Abbassi, MM1
Youssry, I1
Andraues, NG1
Hassany, M1
Selim, YMM1
El-Sayed, MH1
Li, X1
Jiao, Y1
Xing, Y1
Gao, P1
Goto, K1
Lin, W1
Zhang, L1
Jilg, N1
Shao, RX1
Schaefer, EA1
Zhao, H1
Fusco, DN1
Peng, LF1
Kato, N1
Chung, RT1
Llovet, JM1
Zucman-Rossi, J1
Pikarsky, E1
Sangro, B1
Schwartz, M1
Sherman, M1
Gores, G1
Doyle, MA1
Singer, J1
Lee, T1
Muir, M1
Cooper, C1
Kasmari, AJ1
Welch, A1
Liu, G1
Leslie, D1
McGarrity, T1
Riley, T1
Trask, LE1
Abbott, D1
Lee, HK1
Yu, JW1
Sun, LJ1
Zhao, YH1
Kang, P1
Yan, BZ1
del Campo, JA1
García-Valdecasas, M1
Rojas, L1
Rojas, Á1
Romero-Gómez, M1
Huang, H1
Kang, R1
Wang, J1
Luo, G1
Yang, W1
Zhao, Z1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744]Phase 2112 participants (Anticipated)Interventional2021-08-03Recruiting
Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451]Phase 1/Phase 2120 participants (Actual)Interventional2020-07-27Completed
Improving Treatment and Liver Fibrosis Outcomes With Metformin in HCV-HIV Co-infected and HCV Mono-infected Patients With Insulin Resistance.[NCT02306070]Phase 20 participants (Actual)Interventional2016-01-31Withdrawn (stopped due to insufficient funding)
Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch Followed by Ledipasvir-Sofosbuvir HCV Therapy in HIV-HCV Co-Infection: A CIHR Canadian HIV Trials Network-Gilead Pilot Trial Proposal[NCT02660905]Phase 325 participants (Actual)Interventional2016-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for metformin and Hepatitis C

ArticleYear
Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis.
    BioMed research international, 2019, Volume: 2019

    Topics: Alcoholism; Diabetes Complications; Diabetes Mellitus; Glucose; Hepacivirus; Hepatitis B; Hepatitis

2019
Hepatocellular carcinoma.
    Nature reviews. Disease primers, 2016, 04-14, Volume: 2

    Topics: Aflatoxin B1; Alcohol Drinking; Carcinoma, Hepatocellular; Fibrosis; Hepatitis B; Hepatitis B Vaccin

2016

Trials

3 trials available for metformin and Hepatitis C

ArticleYear
The potential hepatoprotective effect of metformin in hepatitis C virus-infected adolescent patients with beta thalassemia major: Randomised clinical trial.
    International journal of clinical practice, 2021, Volume: 75, Issue:6

    Topics: Adolescent; beta-Thalassemia; Child; Hepacivirus; Hepatitis C; Humans; Metformin; Prospective Studie

2021
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial.
    Trials, 2016, 07-20, Volume: 17, Issue:1

    Topics: Clinical Protocols; Coinfection; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Liver Cirr

2016
The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2012, Volume: 16, Issue:6

    Topics: Adult; Antibodies, Viral; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Enzyme-Lin

2012

Other Studies

6 other studies available for metformin and Hepatitis C

ArticleYear
Hepatoprotective effects of metformin in hepatitis C virus-infected adolescents with beta thalassaemia major.
    International journal of clinical practice, 2021, Volume: 75, Issue:12

    Topics: Adolescent; beta-Thalassemia; Hepacivirus; Hepatitis C; Humans; Metformin

2021
The AMPK-related kinase SNARK regulates hepatitis C virus replication and pathogenesis through enhancement of TGF-β signaling.
    Journal of hepatology, 2013, Volume: 59, Issue:5

    Topics: Biopsy; Cell Line; Gene Expression Regulation; Hepacivirus; Hepatitis C; Humans; Liver; Metformin; P

2013
Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome.
    The American journal of medicine, 2017, Volume: 130, Issue:6

    Topics: Adult; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus, Type 2; Female; Hepatitis C; Human

2017
Low hemoglobin A(1c)--good diabetic control?
    Clinical chemistry, 2012, Volume: 58, Issue:3

    Topics: Anemia; Diabetes Mellitus, Type 2; Erythropoietin; Female; Glycated Hemoglobin; Hepatitis C; Humans;

2012
The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance.
    PloS one, 2012, Volume: 7, Issue:10

    Topics: Cell Line; Comorbidity; Gene Expression Profiling; Gene Expression Regulation; Gene Expression Regul

2012
Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy.
    Autophagy, 2013, Feb-01, Volume: 9, Issue:2

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Autophagy; Autophagy-Related Protein-1 Ho

2013